Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study
Liver International · 2025
DOI: 10.1111/liv.16158 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Carine Nicolas und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive and Hepatobiliary Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Hepacivirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Hepatitis C virus genotype 5 (HCV‐GT‐5) is found mainly in South Africa. In our area in central France, the prevalence of HCV‐GT‐5 is 14%. Methods and Results Here we evaluated sustained virological response at week 12 post‐treatment (SVR12) in 147 HCV‐GT‐5 patients from 14 French university hospitals (2014–2021) treated with direct‐acting antivirals (DAA) in real‐life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure.
Conclusions
HCV‐GT‐5 patients treated with a DAA regimen had a 99% SVR12 in intention‐to‐treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real‐world HCV‐GT‐5 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Digestive and Hepatobiliary Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.
- Oncology and Medical-Surgical Specialities, Department of Hepatology, AP-HP/Hôpital Cochin, Paris-Cité University/INSERM U1223-U1016, Paris, France.
- Department of Liver Diseases, CHU Rennes, Rennes University/UMR124/INSERM CIC1414, Institut NUMECAN, Rennes, France.
- Department of Hepato-Gastroenterology, CHU Limoges, Limoges University/INSERM U1248, Limoges, France.
- Department of Hepatology, CHU Toulouse, Toulouse, France.
- Department of Hepato-Gastroenterology, AP-HP/Hôpital Beaujon, Paris-Cité University/CRI/INSERM UMR1149, Paris, France.
ORCID-Profile: Carine Nicolas, Stanislas Pol, Edouard Bardou-Jacquet, Dominique Thabut
Zitieren
APA
Nicolas, C., Domas, Q., Pol, S., Bardou-Jacquet, E., Loustaud-Ratti, V., Métivier, S., Asselah, T., Thabut, D., Bourlière, M., Mathurin, P., Foucher, J., Larrey, D., Varaut, A., Alric, L., Bailly, F., Muti, L., Buchard, B., & Abergel, A. (2025). Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study. Liver International. https://doi.org/10.1111/liv.16158
Vancouver
Nicolas C, Domas Q, Pol S, Bardou-Jacquet E, Loustaud-Ratti V, Métivier S, et al. Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study. Liver International. 2025. doi:10.1111/liv.16158
BibTeX
@article{Nicolas2025,
author = {Nicolas, Carine and Domas, Quentin and Pol, Stanislas and Bardou-Jacquet, Edouard and Loustaud-Ratti, Véronique and Métivier, Sophie and Asselah, Tarik and Thabut, Dominique and Bourlière, Marc and Mathurin, Philippe and Foucher, Juliette and Larrey, Dominique and Varaut, Anne and Alric, Laurent and Bailly, François and Muti, Léon and Buchard, Benjamin and Abergel, Armando},
title = {Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.16158}
}
EUVIMED